569397 Staurosporine, Streptomyces sp.

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₂₈H₂₆N₄O₃ 62996-74-1

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
569397-100UG
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 100 μg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      569397-1MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Plastic ampoule 1 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          569397-250UG
          Retrieving availability...
          Limited AvailabilityLimited Availability
          Stocked 
          Discontinued
          Limited Quantities Available
          Available
            Remaining : Will advise
              Remaining : Will advise
              Will advise
              Contact Customer Service
              Contact Customer Service

              Plastic ampoule 250 μg
              Retrieving price...
              Price could not be retrieved
              Minimum Quantity needs to be mulitiple of
              Upon Order Completion More Information
              You Saved ()
               
              Request Pricing
              Description
              OverviewA potent, cell-permeable, reversible, ATP-competitive and broad spectrum inhibitor of protein kinases. Inhibits protein kinase A (IC50 = 7 nM), CaM kinase (IC50 = 20 nM), myosin light chain kinase (IC50 = 1.3 nM), protein kinase C (IC50 = 700 pM), and protein kinase G (IC50 = 8.5 nM). Also inhibits platelet aggregation induced by collagen or ADP but has no effect on thrombin-induced platelet aggregation. Induces apoptosis in human malignant glioma cell lines. Arrests normal cells at the G1 checkpoint. A 1 mM (100 µg/214 µl) solution of Staurosporine (Cat. No. 569396) in DMSO is also available.
              Catalogue Number569397
              Brand Family Calbiochem®
              SynonymsMLCK Inhibitor I, PKA Inhibitor II
              References
              ReferencesCouldwell, W.T., et al. 1994. FEBS Lett. 345, 43.
              Nishimura, H. and Simpson, I.A. 1994. Biochem. J. 302, 271.
              Bruno, S., et al. 1992. Cancer Res. 52, 470.
              Kiss, Z. and Deli, E. 1992. Biochem. J. 288, 853.
              Vitale, M.L., et al. 1992. Neuroscience 51, 463.
              Hoffman, R. and Newland, E.S. 1991. Cancer Chemother. Pharmacol. 28, 102.
              Oka, S., et al. 1986. Agric. Biol. Chem. 50, 2723.
              Product Information
              CAS number62996-74-1
              ATP CompetitiveY
              FormWhite to pale yellow solid
              Hill FormulaC₂₈H₂₆N₄O₃
              Chemical formulaC₂₈H₂₆N₄O₃
              ReversibleY
              Structure formula ImageStructure formula Image
              Quality LevelMQ100
              Applications
              Biological Information
              Primary TargetPKA
              Primary Target IC<sub>50</sub>7 nM, 20 nM, 1.3 nM, 700 pM, and 8.5 nM against protein kinase A , CaM kinase, myosin light chain kinase, protein kinase C, and protein kinase G, respectively
              Purity≥99% by HPLC
              Physicochemical Information
              Cell permeableY
              Dimensions
              Materials Information
              Toxicological Information
              Safety Information according to GHS
              Safety Information
              Product Usage Statements
              Storage and Shipping Information
              Ship Code Ambient Temperature Only
              Toxicity Standard Handling
              Storage +2°C to +8°C
              Protect from Light Protect from light
              Do not freeze Ok to freeze
              Special InstructionsFollowing reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to 6 months at -70°C.
              Packaging Information
              Packaged under inert gas Packaged under inert gas
              Transport Information
              Supplemental Information
              Specifications

              Documentation

              Staurosporine, Streptomyces sp. SDS

              Title

              Safety Data Sheet (SDS) 

              Staurosporine, Streptomyces sp. Certificates of Analysis

              TitleLot Number
              569397

              References

              Reference overview
              Couldwell, W.T., et al. 1994. FEBS Lett. 345, 43.
              Nishimura, H. and Simpson, I.A. 1994. Biochem. J. 302, 271.
              Bruno, S., et al. 1992. Cancer Res. 52, 470.
              Kiss, Z. and Deli, E. 1992. Biochem. J. 288, 853.
              Vitale, M.L., et al. 1992. Neuroscience 51, 463.
              Hoffman, R. and Newland, E.S. 1991. Cancer Chemother. Pharmacol. 28, 102.
              Oka, S., et al. 1986. Agric. Biol. Chem. 50, 2723.

              Brochure

              Title
              PKC Pathway Poster PDF ( 676 KB )

              Citations

              Title
            • Joao B. Oliveira, et al. (2007) NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Procedings of the National Academy of Science 104, 8953-8958.
            • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
            • Rick B. Vega, et al. (2004) Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5. Molecular and Cellular Biology 24, 8374-8385.
            • Data Sheet

              Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

              Revision17-July-2014 JSW
              SynonymsMLCK Inhibitor I, PKA Inhibitor II
              DescriptionA potent, cell-permeable, reversible, ATP-competitive and broad spectrum inhibitor of protein kinases. Inhibits CaM kinase (IC50 = 20 nM), myosin light chain kinase (IC50 = 1.3 nM), protein kinase A (IC50 = 7 nM), protein kinase C (IC50 = 0.7 nM), and protein kinase G (IC50 = 8.5 nM). Also inhibits platelet aggregation induced by collagen or ADP but has no effect on thrombin-induced platelet aggregation. Induces apoptosis in human malignant glioma cell lines. Arrests normal cells at the G1 checkpoint.
              FormWhite to pale yellow solid
              Intert gas (Yes/No) Packaged under inert gas
              CAS number62996-74-1
              Chemical formulaC₂₈H₂₆N₄O₃
              Structure formulaStructure formula
              Purity≥99% by HPLC
              SolubilityDMSO (5 mg/ml). Further dilute with aqueous buffers just prior to use.
              Storage +2°C to +8°C
              Protect from light
              Do Not Freeze Ok to freeze
              Special InstructionsFollowing reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to 6 months at -70°C.
              Toxicity Standard Handling
              ReferencesCouldwell, W.T., et al. 1994. FEBS Lett. 345, 43.
              Nishimura, H. and Simpson, I.A. 1994. Biochem. J. 302, 271.
              Bruno, S., et al. 1992. Cancer Res. 52, 470.
              Kiss, Z. and Deli, E. 1992. Biochem. J. 288, 853.
              Vitale, M.L., et al. 1992. Neuroscience 51, 463.
              Hoffman, R. and Newland, E.S. 1991. Cancer Chemother. Pharmacol. 28, 102.
              Oka, S., et al. 1986. Agric. Biol. Chem. 50, 2723.
              Citation
            • Joao B. Oliveira, et al. (2007) NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Procedings of the National Academy of Science 104, 8953-8958.
            • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
            • Rick B. Vega, et al. (2004) Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5. Molecular and Cellular Biology 24, 8374-8385.
            • Related Products & Applications

              Categories

              Life Science Research > Inhibitors and Biochemicals > Small Molecules & Inhibitors > Protein Phosphorylation / Dephosphorylation > Protein Kinase G (PKG; cGMP-Dependent Protein Kinase) Inhibitors
              Life Science Research > Inhibitors and Biochemicals > Small Molecules & Inhibitors > Protein Phosphorylation / Dephosphorylation > Protein Kinase A (PKA; cAMP-Dependent Protein Kinase) Inhibitors
              Life Science Research > Inhibitors and Biochemicals > Small Molecules & Inhibitors > Protein Phosphorylation / Dephosphorylation > Protein Kinase C (PKC) Inhibitors